Q1 EPS Estimates for Legend Biotech Lowered by HC Wainwright

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Equities researchers at HC Wainwright reduced their Q1 2026 earnings per share (EPS) estimates for shares of Legend Biotech in a note issued to investors on Monday, March 16th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.04) per share for the quarter, down from their prior estimate of $0.04. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech’s FY2026 earnings at $0.42 EPS.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings data on Tuesday, March 10th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.18. Legend Biotech had a negative return on equity of 21.93% and a negative net margin of 28.86%.The firm had revenue of $306.30 million during the quarter, compared to the consensus estimate of $310.21 million. During the same period in the prior year, the business earned $0.07 EPS. The firm’s revenue was up 64.2% on a year-over-year basis.

LEGN has been the subject of several other research reports. Royal Bank Of Canada lowered their price target on shares of Legend Biotech from $66.00 to $62.00 and set an “outperform” rating for the company in a research report on Wednesday, March 11th. Barclays reduced their target price on shares of Legend Biotech from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Wednesday, February 4th. Jefferies Financial Group restated a “buy” rating and issued a $69.00 target price on shares of Legend Biotech in a research report on Tuesday, March 10th. Cantor Fitzgerald dropped their price target on shares of Legend Biotech from $75.00 to $74.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 17th. Finally, Raymond James Financial reaffirmed an “outperform” rating on shares of Legend Biotech in a report on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $58.31.

Legend Biotech Stock Performance

LEGN stock opened at $17.41 on Thursday. Legend Biotech has a 1 year low of $16.24 and a 1 year high of $45.30. The stock has a market capitalization of $3.22 billion, a price-to-earnings ratio of -21.76 and a beta of 0.07. The stock’s fifty day moving average is $18.98 and its two-hundred day moving average is $25.70.

Hedge Funds Weigh In On Legend Biotech

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Clearstead Advisors LLC raised its position in shares of Legend Biotech by 76.5% during the 3rd quarter. Clearstead Advisors LLC now owns 847 shares of the company’s stock worth $28,000 after buying an additional 367 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of Legend Biotech by 171.9% in the third quarter. Parallel Advisors LLC now owns 1,047 shares of the company’s stock valued at $34,000 after acquiring an additional 662 shares in the last quarter. OFI Invest Asset Management increased its stake in shares of Legend Biotech by 102.6% during the third quarter. OFI Invest Asset Management now owns 1,228 shares of the company’s stock valued at $40,000 after acquiring an additional 622 shares during the period. Caitong International Asset Management Co. Ltd increased its stake in shares of Legend Biotech by 1,730.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,569 shares of the company’s stock valued at $78,000 after acquiring an additional 3,374 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in Legend Biotech during the second quarter worth approximately $78,000. Institutional investors own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.